MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
20 April 2015
Melanoma Institute Australia and its key affiliate, Crown Princess Mary Cancer Centre Westmead were the highest recruiting centre worldwide for the study into the immunotherapies pembrolizumab versus ipilimumab, in advanced melanoma, with the findings published in the New England Journal of Medicine, the leading medical journal in the world.
The study found that the anti–PD-1 antibody pembrolizumab (trade name KEYTRUDA®) prolonged survival, and had less high-grade toxicity, compared with ipilimumab (trade name YERVOY®) in patients with advanced melanoma, that is, melanoma that has spread to distant parts of the body.
Associate Professor Georgina Long from Melanoma Institute Australia and University of Sydney said, “Here at MIA and Westmead we have been undertaking clinical trials with immunotherapy treatment using anti-PD-1 drugs for over three years, and these findings are the final piece of data that show the anti–PD-1 antibody pembrolizumab is better than current treatments for patients with advanced melanoma.”
The immune checkpoint inhibitor, ipilimumab, is one of the standard treatments for patients with advanced melanoma. The latest findings show that pembrolizumab, which inhibits the programmed death receptor 1 (PD-1) immune checkpoint on immune T cells, has antitumor activity: that is, it reduces the size of the tumours in patients with advanced melanoma in approximately 70% of patients, with deep reduction in over 30%, and prolongs survival compared with ipilimumab.
This clinical trial using pembrolizumab (KEYTRUDA®) recorded a 1 year survival rate of 74%, whilst those who received ipilimumab (YERVOY®) had a 1 year survival rate of 58%. Five years ago, only 30-35% of patients with advanced melanoma survived 1-year.
“These results are world-first, where two effective immunotherapies are directly compared, and we significantly improve outcomes for patients even further. This is great news for Australia, which has the highest incidence of melanoma in the world, and an Australian dies from this disease every 6 hours” said Assoc Prof Georgina Long. “This is evidence which will be considered by bodies around the world, including the Australian Government, to make these drugs accessible to all melanoma patients".
Research Co-Director of Melanoma Institute Australia and Macquarie University Professor Rick Kefford claims, “this breakthrough is probably the most important development in the treatment of this disease ever, and a landmark in terms of cancer treatment in general.”
Others Australian centres involved in this trial include: Newcastle Melanoma Unit, NSW; The Austin Hospital, VIC; Sir Charles Gardiner Hospital, WA; Princes Alexandra Hospital, QLD; Sydney Cancer Centre, RPAH, NSW.
Little Madi misses her Dad. But she is determined to honour his memory and support life-saving melanoma research.
Toyota and country music fans invited to tip their hat to help tackle Australia's national cancer – melanoma
Melanoma Institute Australia has teamed up with the Toyota Country Music Festival 2018 in Tamworth!
MIA's dermatologist shares her knowledge with GPs on debunking myths and controversies on sunscreen.
Shannan Ponton thought he was invincible – he wasn’t. But his melanoma battle ended up saving more than his own life.
Researchers have demonstrated that immunotherapy is highly effective in treating a rare form of melanoma – a result that is surprising due to the nature of the tumour.
Innovation is helping to prevent melanoma developing in the first place.
Research from MIA is changing the way melanoma is managed worldwide and improving patient survival. Here are a few of our key highlights from this year.
A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.
New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.